Business Context and Reporting Period
This Form 8-K Current Report was filed by Spruce Biosciences, Inc. on March 14, 2022, reporting an event that occurred on February 25, 2022. The Company is a Delaware corporation with its principal executive offices in Daly City, California, and its common stock trades on the Nasdaq Global Select Market under the symbol "SPRB".
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on a capital raising mechanism.
Material Changes
The material change reported is the entry into an Open Market Sale Agreement with Jefferies LLC. Key terms include:
- Offering Capacity: The Company may offer and sell shares of common stock with an aggregate offering price of up to $21.0 million.
- Sales Method: Shares may be sold "at the market" through Jefferies as agent, including sales on or through the Nasdaq Global Select Market.
- Commission: The Company agreed to pay Jefferies a commission of 3.0% of the gross proceeds from the sale of shares.
- Flexibility: The Company is not obligated to sell any shares and may instruct Jefferies to suspend or terminate sales if prices fall below designated levels.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future operational outlook. The primary contingency noted is that the offering is subject to market conditions and the Company's discretion to halt sales. The Company is classified as an emerging growth company.
Investor Verification Checklist
- Verify the current share price and trading volume to assess the potential dilution impact of a $21.0 million offering.
- Review the Company's most recent Form 10-K or 10-Q to understand current cash reserves and the necessity of this capital raise.
- Confirm the total number of shares authorized for sale under the existing shelf Registration Statement (File No. 333-261960).
- Monitor subsequent filings for actual sales volumes and proceeds generated under the agreement.